Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast CancerBusiness Wire • 10/07/26
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026PRNewsWire • 10/06/26
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher24/7 Wall Street • 10/06/26
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips24/7 Wall Street • 10/05/26
Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside24/7 Wall Street • 10/05/26
Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income.The Motley Fool • 10/05/26
Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental VitiligoBusiness Wire • 10/02/26
Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.The Motley Fool • 10/02/26
Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More AttractiveThe Motley Fool • 10/01/26
Trump Medicare drug pricing model may apply to only four companies after exemptionsReuters • 10/01/26